Radiochemistry & Molecular Imaging Probes
Overview
Jason S. Lewis
Scientific Director
At Memorial Sloan Kettering, researchers have translated numerous new radiopharmaceuticals into the clinic for both imaging and therapy purposes. The Radiochemistry and Molecular Imaging Probe (RMIP) Core Facility serves these investigators by supplying a variety of radiopharmaceuticals , including radiolabeled small molecules, peptides, antibodies, and nanoparticles that can be imaged by methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). It also supplies nonradioactive molecular imaging probes for use with non-nuclear detection systems. Our services support both basic research investigations and patient imaging.
Featured News
In the Clinic
How Our New Particle Accelerator Will Make Cancer Imaging and Treatment More Precise
The launch of a 20-ton instrument and a facility for producing radioactive imaging molecules will allow our doctors and scientists to monitor cancers in unparalleled detail.
Novel Cancer-Targeting Investigational Nanoparticle Receives FDA IND Approval for First-In-Human Trial
Researchers at Memorial Sloan Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
People
Members
Andrew Rivera
Radiopharmacy Tech I
Christopher Yung
RMIP Core Radiopharmacist
Ariel Brown
Radiopharmacy QA Specialist
Phillip DeNoble
RMIP Core Radiopharmacist
Yorann Roux
Clinical Radiochemist
Yiauchung "Howard" Sheh
Senior Cyclotron Engineer
Kevin Staton
Project Manager, Funds
Tristan Tiongson
RMIP Core Radiopharmacist
Alumni
Get in Touch
-
Director Email